IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.